TMEM16A Potentiators: Is There a Need for New Modulators in Cystic Fibrosis?
Open Access
- 15 April 2020
- journal article
- editorial
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 201 (8) , 888-889
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical ImplicationsAmerican Journal of Respiratory and Critical Care Medicine, 2020
- TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2020
- Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trialThe Lancet, 2019
- Functional Apical Large Conductance, Ca2+-activated, and Voltage-dependent K+ Channels Are Required for Maintenance of Airway Surface Liquid VolumeJournal of Biological Chemistry, 2011
- Expression Cloning of TMEM16A as a Calcium-Activated Chloride Channel SubunitCell, 2008
- TMEM16A confers receptor-activated calcium-dependent chloride conductanceNature, 2008
- Extracellular purines are biomarkers of neutrophilic airway inflammationEuropean Respiratory Journal, 2008
- Normal and Cystic Fibrosis Airway Surface Liquid HomeostasisJournal of Biological Chemistry, 2005
- Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia.Proceedings of the National Academy of Sciences, 1991
- Chloride secretory response of cystic fibrosis human airway epithelia. Preservation of calcium but not protein kinase C- and A-dependent mechanisms.Journal of Clinical Investigation, 1989